OpenEvidence
 | |
 | |
| Type | Private |
|---|---|
| Industry | Artificial intelligence Healthcare technology |
| Founded | 2022 |
| Founders | Daniel Nadler, Zachary Ziegler |
| Headquarters | Miami, Florida, United States |
Area served | United States |
Key people | Daniel Nadler (Co-founder & CEO) Zachary Ziegler (Co-founder) |
| Total equity | $12 billion (2026) |
| Website | www |
OpenEvidence is the name for both the product (an LLM) and the company, an American artificial intelligence company that develops a medical search engine, which is used by healthcare professionals for clinical decision making support. The company was founded in 2022 by entrepreneur Daniel Nadler and is headquartered in Miami, Florida.[1] As of January 2026, the company is valued at $12 billion, following several funding rounds.[2]
History
[edit]OpenEvidence was founded in 2022 by Daniel Nadler, a Harvard Ph.D. and former founder of Kensho, a financial analytics firm acquired by S&P Global in 2018.[3][4] Nadler launched the company with co-founder Zack Ziegler, a machine learning researcher from Harvard, to address the challenge physicians face in keeping up with the growing volume of medical literature.[1][5]
In 2023, OpenEvidence reported that its artificial intelligence model achieved a 90 percent score on the United States Medical Licensing Examination (USMLE).[6] During the same year, the company participated in the Mayo Clinic health-technology accelerator.[7] In 2025, the company stated that the model had reached a 100 percent score on the same examination.[5][8]
In February 2025, OpenEvidence raised $75 million in a Series A round led by Sequoia Capital, valuing the company at $1 billion.[9] In July 2025, the company secured $210 million in funding from a round led by GV (Google Ventures) and Kleiner Perkins, with participation from Coatue, Conviction, and Thrive Capital. This round valued the company at $3.5 billion.[10] In April 2025, OpenEvidence was featured in the Forbes AI 50 list.[11]
OpenEvidence has established content licensing partnerships with several medical organizations and journals, including American Medical Association, National Comprehensive Cancer Network (NCCN), American Academy of Family Physicians, American College of Emergency Physicians, New England Journal of Medicine, Journal of the American Medical Association, JAMA Network, JAMA Oncology, and JAMA Neurology.[12][5][13][14] [15][5][13][14]
On October 20th 2025, the company announced a US$200 million Series C funding round, valuing the company at US$6 billion.[16] As of December 2025, the company reported 760,000 registered U.S. physicians and approximately 18 million clinical consultations per month.[17] In January 2026, OpenEvidence raised $250 million in a Series D funding round at a $12 billion valuation.[18][19] As of early 2026, OpenEvidence had raised approximately $700 million in total funding from investors including Google Ventures, Nvidia, Sequoia, Blackstone, Thrive Capital, Kleiner Perkins, Craft Ventures and Mayo Clinic.[20]
Partnerships
[edit]In May 2026, OpenEvidence partnered with Cedars-Sinai to integrate its decision support platform into the hospital's electronic health record infrastructure.[21] The integration allows healthcare professionals to query medical literature using patient-specific clinical context.[22]
Product and technology
[edit]OpenEvidence provides a Large Language Model with an artificial intelligence-based platform that analyzes and organizes peer-reviewed medical literature from clinical journals such as The New England Journal of Medicine and The Journal of the American Medical Association. According to the company, access is available at no cost to verified physicians, with revenue derived from advertising. As of July 2025, the company reported more than 430,000 registered U.S. physicians (about 40% of U.S. physicians) and use in over 8.5 million consultations per month. In the same month, OpenEvidence introduced a feature called DeepConsult, described as employing reasoning models to synthesize findings across multiple studies.[7]
In May 2026, the company introduced Voice Mode, a voice-based interface for its platform that was made available through the company's web and mobile applications.[23]
Practitioners can utilize the platform with their National Practitioner Identity numbers to create an account free of charge. When prompting an inquiry OpenEvidence will then begin referencing published medical journals to provide seemingly up to date information, and suggestion on clinical topics.
Recognition
[edit]In 2025, Daniel Nadler, co-founder of OpenEvidence, was named to the TIME100 Health list of the 100 most influential people in global health.[24]
See also
[edit]References
[edit]- 1 2 Feldman, Amy. "OpenEvidence Cofounder Daniel Nadler Is Now A Billionaire". Forbes. Retrieved 2025-10-03.
- ↑ "Medical AI startup OpenEvidence doubles valuation to $12 billion in latest round". Reuters. 2026-01-21.
- ↑ Bertoni, Steven. "Can Kensho Bring Google Style Search To Stock Picking?". Forbes. Retrieved 2025-10-03.
- ↑ Gara, Antoine. "Wall Street Tech Spree: With Kensho Acquisition S&P Global Makes Largest A.I. Deal In History". Forbes. Retrieved 2025-10-03.
- 1 2 3 4 Landi, Heather (2025-08-15). "OpenEvidence AI scores 100% on USMLE, launches explanation model". www.fiercehealthcare.com. Retrieved 2025-10-01.
- ↑ Roger, Olivia (July 14, 2023). "OpenEvidence's gen AI bests ChatGPT, Med-PaLM 2 on US medical licensing exam". firstwordhealthtech.com. Retrieved 2025-10-03.
- 1 2 Feldman, Amy. "How OpenEvidence Cofounder Daniel Nadler Became A Billionaire". Forbes ME. Retrieved 2025-10-03.
- ↑ "Medical AI Firm Says Competitor Hacked Prompts to Steal Secrets". 2025-06-23. Archived from the original on 2025-07-24. Retrieved 2025-10-03.
- ↑ Rooney, Kate (2025-02-19). "AI health-care startup OpenEvidence raises funding from Sequoia at $1 billion valuation". CNBC. Retrieved 2025-10-03.
- ↑ Balasubramanian, Sai. "OpenEvidence's Meteoric Rise Is Huge For Doctors". Forbes. Retrieved 2025-10-03.
- ↑ SHRIVASTAVA"], ["RASHI. "Forbes 2025 AI 50 List - Top Artificial Intelligence Companies Ranked". Forbes. Archived from the original on 2025-12-31. Retrieved 2026-01-12.
- ↑ "NCCN Guidelines to Be Integrated Into OpenEvidence's Medical AI Platform". ascopost.com. 11 July 2025. Retrieved 2026-02-24.
- 1 2 Haupt, Angela. "TIME100 Health: Daniel Nadler". TIME. Archived from the original on 2025-06-16. Retrieved 2025-10-03.
- 1 2 "How What is OpenEvidence? AI Medical Search for Physicians". aiforsocialgood.ca. 2025-10-15. Retrieved 2025-10-15.
- ↑ Landi, Heather (2026-01-21). "OpenEvidence clinches $250M, doubles valuation to $12B". www.fiercehealthcare.com. Retrieved 2026-02-22.
- ↑ "OpenEvidence Raises $200 Million for a ChatGPT for Medicine". The New York Times. 2025-10-20. Retrieved 2025-11-11.
- ↑ Landi, Heather (2026-01-21). "OpenEvidence clinches $250M, doubles valuation to $12B". www.fiercehealthcare.com. Retrieved 2026-02-24.
- ↑ "Medical AI startup OpenEvidence doubles valuation to $12 billion in latest round". EnterpriseAI (from The Economic Times). 2026-01-22.
- ↑ Kate Rooney (January 21, 2026). "OpenEvidence, the 'ChatGPT for doctors,' doubles valuation to $12 billion". CNBC. Retrieved January 26, 2026.
- ↑ Shrivastava, Rashi. "AI Founder Daniel Nadler Is Twice As Rich After OpenEvidence Hits $12 Billion Valuation". Forbes. Archived from the original on 2026-02-17. Retrieved 2026-02-22.
- ↑ Landi, Heather (2026-05-21). "OpenEvidence CEO says AI enterprise model in the works". www.fiercehealthcare.com. Retrieved 2026-08-22.
- ↑ Martinez, Cara (May 20, 2026). "Cedars-Sinai and OpenEvidence Partner on AI Health Solution". cedars-sinai.org. Retrieved 2026-08-22.
- ↑ "OpenEvidence Brings Hands-Free Medical AI to 860,000 Clinicians". PYMNTS.com. 2026-05-21. Retrieved 2026-08-22.
- ↑ "TIME100 Health 2025". TIME. 2026-03-17. Retrieved 2026-08-22.